secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0000950170-24-054442
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reneo Pharmaceuticals initiates strategic alternatives review after failed trial; Q1 net loss $8.4M
--------------------------------------------------------------------------------

- STRIDE study of mavodelpar in primary mitochondrial myopathies missed all endpoints in Dec 2023.
- Suspended all mavodelpar development; reduced workforce by ~90% in Dec 2023 and Feb 2024.
- Retained independent financial advisor to explore strategic alternatives, including possible sale.
- Q1 2024 net loss $8.4M ($0.25/share) vs $15.1M ($0.60/share) Q1 2023; cash $82.8M as of Mar 31, 2024.
- R&D expenses fell to $4.9M from $11.0M due to program suspension and cost-cutting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000095017024054442/0000950170-24-054442-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000095017024054442/rphm-20240507.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-054442

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer